GlassScriptPhysician profile
Casey A Taylor
NPI 1922603976
$6,870.30
in general payments reported to CMS, 2019-2025
21 companies · $2,057 in 2025
The $2,057 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $508 · 2022: $861 · 2023: $1,381 · 2024: $2,064 · 2025: $2,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,501.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,800.67 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,468.75 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $721.55 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.62 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $518.49 | 2021-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Exact Sciences Corporation | $387.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $284.82 | 2023-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $179.78 | 2021-2024 | Xarelto |
| Pfizer INC. | $155.85 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $151.93 | 2023-2024 | Gvoke Hypopen |
| Lilly USA, LLC | $127.29 | 2025 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $123.45 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.09 | 2025 | Caplyta |
| Verona Pharma, INC. | $69.97 | 2025 | Ohtuvayre |
| E.R. Squibb & Sons, L.L.C. | $54.54 | 2024 | Eliquis, Camzyos |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $48.73 | 2023-2024 | Belbuca |
| Merck Sharp & Dohme LLC | $37.61 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amarin Pharma, INC. | $33.74 | 2021 | |
| Ibsa Pharma INC. | $22.96 | 2024 | Licart, Tirosint |
| Biohaven Pharmaceuticals, INC. | $21.99 | 2021 | |
| Corium, LLC | $14.46 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.